Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
mara.cenerenti@ndcls.ox.ac.uk

Mara Cenerenti

Postdoctoral researcher

I hold a B.S. in Biological Science from the University of Milan-Bicocca and an M.S. in Molecular Biotechnology and Bioinformatics from the University of Milan. In 2024, I completed the PhD at the University of Geneva (Switzerland), where I investigated the cytotoxic properties of tumor-specific CD4 T cells in human melanoma in the laboratory of Prof. Camilla Jandus. Currently, I am a Postdoctoral Scientist at the Weatherall Institute of Molecular Medicine (WIMM) at the University of Oxford, working in the laboratory of Prof. Ronjon Chakraverty on pioneering advancements in T cell therapeutics.

Recent publications

Engineered CD4 TCR T cells with conserved high-affinity TCRs targeting NY-ESO-1 for advanced cellular therapies in cancer.

Saillard M. et al, (2025), Sci Adv, 11

Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy.

Wang C. et al, (2024), Cell, 187, 2690 - 2702.e17

Dendritic cells direct circadian anti-tumour immune responses.

Wang C. et al, (2023), Nature, 614, 136 - 143

Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability.

Forte D. et al, (2023), Front Immunol, 14

The Era of Cytotoxic CD4 T Cells.

Cenerenti M. et al, (2022), Front Immunol, 13

More publications